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Abstract
The integration of original data from multiple antiretroviral (ARV) adherence studies offers a
promising, but little used method to generate evidence to advance the field. This paper provides an
overview of the design and implementation of MACH14, a collaborative, multi-site study in which
a large data system has been created for integrated analyses by pooling original data from 16
longitudinal ARV adherence studies. Studies selected met specific criteria including similar
research design and data domains such as adherence measured with medication event monitoring
system, psychosocial factors related to adherence behavior, and virologic and clinical outcomes.
The data system created contains individual data (collected between 1997 and 2009) from 2,860
HIV patients. Collaboration helped resolve the challenges inherent in pooling data across multiple
studies, yet produced a data system with strong statistical power and potentially greater capacity to
address key scientific questions than possible with single-sample studies or even meta-analytic
designs.
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Introduction
Adherence to antiretroviral therapy (ART) has proved to be vital to its success, yet research
on ART adherence has been stymied by studies of self-reported adherence with small
samples. Highly active antiretroviral therapy (HAART) has led to a striking decrease in both
morbidity and mortality related to HIV/AIDS infection [1–4]. Research indicates that
adherence to HAART is the strongest predictor of viral suppression, resistance, disease
progression and death [4–6]. To provide optimal HIV care, clinicians and researchers need
to understand the predictors of adherence to HAART and its influence on HIV health
outcomes. Different measures and aspects of HAART adherence have been examined in a
host of studies for more than a decade. This research has substantially improved our
understanding of HAART adherence, however our knowledge remains incomplete. Different
approaches to adherence measurement have made it difficult to compare findings across
studies and limited researchers' ability to explain the inconsistencies observed.
Self-reported adherence measures have been most commonly used. They are valued for their
convenience and practicality. However, scale items and methods of summarizing and
analyzing data have varied considerably from one study to another, and self-reported
measures are criticized for being imprecise in comparison to other types of measures
because self-report is subjective and its accuracy depends on the respondent and factors such
as the accuracy of memory. Although self-reported adherence usually correlates with
virologic outcomes in the expected direction, it is generally found to overestimate adherence
[4, 7–13].
The medication event monitoring system (MEMS), which electronically records the date and
time of pill bottle openings, has the potential to provide a more objective measure of
adherence when used correctly. While MEMS has been associated with virological response,
studies employing MEMS are usually limited in sample size [14–16]. Consequently, most
studies measuring adherence with MEMS have not had sufficient statistical power to
conduct in-depth multivariate analyses of factors in relation with adherence, how these
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relationships change over time, or outcomes of adherence beyond that of viral suppression
such as patterns of resistance, changes in CD4 cell counts, disease progression or death.
To address these limitations, the Multi-site Adherence Collaboration in HIV among 14
institutes (MACH14) study (http://www.mach14.med.ucla.edu/index.htm) was initiated.
This ongoing, NIMH-funded study (R01MH 078773) pools MEMS and other clinically
relevant data from 16 different longitudinal HAART adherence studies to create a large,
diverse HIV data system that can answer questions that are difficult or not feasible to
address using any small, single study. Compared with individual subject-level studies,
pooled data systems are more informative, have stronger statistical power, and can assess
sources of variability across studies as well as between individual subjects. However,
because the MACH14 studies were designed and executed independently, there are a
number of challenges associated with conducting individual subject-level data meta-
analysis. These challenges include non-uniform study entry criteria and varying data timing
(e.g., some studies collected viral load (VL) at specified intervals and others used VLs
collected in the course of routine clinical care), the use of different instruments and different
frequency of measurements for key constructs and missing data—including structurally
missing data (e.g., data never collected, collected once, collected irregularly) and other
missing data (e.g., subject skipped a visit/item on a questionnaire, or dropped out.) Proper
analytical and statistical methods need to be employed to adequately address these issues so
that valid and effective results can be obtained from this unique and powerful pooled HIV
data system.
In this paper, we present the process and methods for developing this first of its kind
collaboration in medication adherence research to help inform future studies that might
benefit from incorporating such methods. We also present the characteristics of individual
studies involved and of their participants and report descriptive statistics of the currently
available domains of the pooled data system. Finally, we discuss additional challenges and
future research directions.
Methods
Development of MACH14 Collaboration and Study Selection
We assembled a list of potential collaborators from the NIH search engine RePORTER
(http://projectreporter.nih.gov/reporter.cfm) to identify studies that used MEMS to study
antiretroviral (ARV) adherence in the United States. Eligible studies were required to have:
(1) a longitudinal study design with at least 3 repeated measurements; (2) MEMS adherence
data; (3) VL and clinical outcomes; and (4) psychosocial and behavioral measures. To
expand our search, we also submitted a formal invitation letter via an HIV adherence email
list to a large pool of HIV adherence researchers. In the end, collaborators from 14 different
institutions were identified. Each had data to contribute from at least one study that met the
eligibility criteria; two of the collaborators had data from two studies, for a total of 16
studies. MACH14 was funded with a 5-year R01 from NIH/NIMH and commenced in June,
2007.
Structure and Management of MACH14
The investigators at each of the 14 institutions worked closely with the Statistical and Data
Coordination Center (S&DCC), which is comprised of methodologists, biostatisticians,
analysts and programmers at the University of California Los Angeles (UCLA). The
S&DCC was responsible for overseeing data transfer, merging and cleaning individual
datasets, and collaborating with sites and conducting statistical analyses. Eight
subcommittees were established to provide expertise in several domains such as MEMS and
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Self-Reported Adherence, Drug Resistance, VL and ARV Medications, Substance Abuse
and Adherence, Adherence Interventions, and Psychosocial Impact. A publication
committee that includes all individual site PIs was also established. The full MACH14 group
conducts monthly conference calls and an annual in-person group meeting; subcommittees
have weekly, bi-weekly or as-needed meetings to discuss analyses and oversee paper-
writing.
Data Preparation and Transfer
Overview of Data Management Procedures—We identified the common domains of
data from the 16 studies: subject demographic characteristics, MEMS adherence, VL and
CD4 levels, drug resistance, self-reported adherence, as well as psychosocial, clinical, and
other domains such as ARV regimen, substance abuse, sexual and behavioral risk, and
adherence intervention. Data systems for each of these domains were first prepared at
individual sites and then transferred to the S&DCC electronically. We chose to maintain
large data systems separately for each domain to provide flexibility in data management and
manipulation by allowing them to be merged with the other relevant datasets to form
different analytical data files that meet the needs of various research questions and
associated analytic plans. The data gathering and management process comprised the
following four steps.
Step One: Creation of Data Preparation Protocols—We first created an Overall
Data Preparation Protocol (ODPP), which stipulates guidelines and principles for preparing
and transferring data, including procedures to maintain data security. The ODPP specified
the domains of data systems to be transferred and the steps needed to be taken at both the
site and S&DCC levels.
Step Two: Data Preparation at Each Study Site—We also created a data information
document (DID) for each domain of the data to be transferred. The DID specified the data
fields required for each subject, including variable names and attributes (e.g., numeric or
character), coding, and units used. A data preparation protocol (DPP) accompanied each
DID and described the procedures to be followed by every site, including the uniform
screening and cleaning process algorithm for MEMS and other data, and the common
definitions of created measures (e.g., race categories). Codebooks containing standard
variable names and coding specifications were produced for each domain. Data preparation
at each site included the conduct of logic, range/outlier, and error checks followed by the
correction of errors discovered. Wherever possible, raw data, not derived variables, were
requested from sites, so that standardized derived variables could be created. For example,
we requested raw data on times of pill cap openings for each individual, not aggregated or
summary adherence data. Each site transferred its prepared datasets to the S&DCC.
Every site and study complied with the data security procedures principles. An analytical ID
for each subject was generated using site-specific scramble functions (accessible only to
PIs). This encrypted ID is the only subject identifier in the analytic files.
Step Three: Data Merging—The S&DCC merged the data received from the sites for
each domain and then re-checked the merged data for errors, collaborating with each site to
correct errors, if any.
Step Four: Analytic Variable Creation—Once the raw data were received, merged and
cleaned, the S&DCC created derived analytic variables. We created for each subject a
summary “percent adherence” variable representing the number of valid pill bottle openings
divided by the number of total openings that would have been expected (based on regimen
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information entered into the MEMS program). If a person's calculated adherence was over
100 %, it was truncated to 100 % in analysis.
The final merged data system contains pooled data from 16 individual studies at 14
institutions across 12 states with more than 50 different domains of measurements and more
than 260 common measures of subject demographics, MEMS, VL and CD4, drug resistance,
self-reported adherence, psychosocial/behavioral factors, substance abuse, sexual risk, and
adherence intervention.
Data Analysis and Statistical Approaches
Data Collection Intervals—Some studies involved regular study visits for data
collection. Among these studies, the interval between study visits varied from every month
to every 3 months. Other studies tied study visits to receipt of clinical care or were
“unannounced” (i.e., for pill counts). Bangsberg and colleagues [4, 17] developed the
unannounced home-base pill count protocol, which relied on subjects to count their own
pills and report the values to an assessor. Some studies collected VL data at specified
intervals, and others used VLs conducted in the course of subjects' routine clinical care.
Thus, for each analysis, decisions were made about how to account for these variations to
allow for the maximum number of studies and subjects to be included in each analysis.
Different Measures Used and Amounts of Data Collected for Key Measures—
Since each of the 16 studies was designed and executed independently of the others,
multiple measures were used across studies to assess the same construct. For example, the
beck depression inventory (BDI), the Patient Health Questionnaire (PHQ-9), and the Center
for Epidemiologic Studies Depression Scale (CES-D) were used to measure depression in
different studies. We created common depression variables by standardizing the different
measures using parameter estimates from normative population data for each scale and then
converting them to z scores or categorizing the different measures into common levels of
depression severity. Similarly, for the sub-domain of anxiety across the studies, the Zung
Anxiety Scale, the Beck Anxiety Index, the State-Trait anxiety Inventory (STAI), and the
Brief Symptom Inventory (BSI) were implemented in different studies.
Different amount of data were collected for some key measures across the studies. To
resolve the heterogeneity and derive common measures that were suitable for analyses, we
created broad classifications that could incorporate most measures. For example, regarding
substance abuse, we developed measures, such as “ever abused drugs or alcohol”, to fit the
situations across the studies.
Viral Load, CD4 and Drug Resistant Data—The key measures in the VL data consist
of subject ID, date of blood drawn, type of lab (e.g., university clinical lab or commercial
lab) and actual lab name, data source(e.g. phlebotomy at study visit, or medical record
abstraction), actual VL reading with lower and upper limit, and lab assay methods such as
quantitative polymerase chain reaction (PCR) or branched-chain DNA (BDNA).
Data on CD4 counts include date of blood drawn, type of lab (i.e., university clinical lab or
commercial lab), and actual lab name and CD4 counts. The drug resistance data contain
measures about gene (protease and reverse transcriptase), codon, substitution, and mutation.
Clinical Data—Clinical measures include lowest ever absolute CD4 count in units of cells/
mm3, highest VL in record in copies/ml or log10 copies/ml, CDC stage A, B, C at time of
entry into study, duration of known HIV status at time of enrollment, ever had an HIV-
related infection or malignancy or complication (e.g., wasting), currently use or ever used
any kind of alternative or complementary medications, treatments, or supplements such as
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vitamins, Chinese herbs, dinitrochlorobenzene (DNCB), Qigong, ever taken or currently on
PCP prophylaxis, and ever taken or currently on TB prophylaxis.
Psychosocial Data—Psychosocial measures include the following sub-domains: self-
efficacy, anxiety, depressive symptoms, social support (general and medication-specific
support) and perceived stress, coping, HIV and ARV related physical symptomatology,
reasons for non-adherence, beliefs about medications, health surveys of health functioning
and quality of life, adherence motivation as well as subjects' perceptions of physicians'
competence and concern.
Adherence Calculation Using MEMS Data—The key measures in MEMS data system
include subject ID, MEMS monitor ID, drug name, prescribed doses per day, the opening
event day and time, time since last opening, and the start and stop date of the monitoring
period. Five studies also collected information on the non-monitored period of MEMS to
indicate when the electronic monitoring was interrupted due to special events and issues
(e.g., for a hospitalization; for imprisonment).
MEMS data were used to calculate medication-specific and overall (across simultaneously
prescribed medications) percent adherence. Overall adherence was calculated as the average
adherence across the multiple ARVs taken. Percent adherence is calculated as the number of
doses recorded by MEMS over the number of prescribed doses for a specific time period.
We also calculated other adherence measures such as dose timing error.
Statistical Approaches—Given that all MACH14 studies had longitudinal designs,
repeated measures mixed effects models (RMMEM) [18] were used as the backbone
approach to model outcomes (e.g., changes in adherence, VL and CD4 over time). RMMEM
has the advantages not only of being able to model global fixed effects (e.g., effects of
gender, race or education on adherence), but also of being able to model the individual
random effects (e.g., changes of adherence over time at subject level). Other modeling
approaches, such as growth curve analysis, generalized estimating equation (GEE), and
survival analysis methods were also used to analyze the data as needed for particular
research questions. Non-linear relationships between outcome measures and predictors and




The S&DCC merged the data received from the sites and re-checked the merged data for
errors. Despite detailed specifications in the DIDs, error checking of the merged data for
each of the domains usually revealed many different challenges. Because each of the 16
studies in MACH14 had different objectives, data collection schedules and analytic plans, a
significant amount of effort was spent to identify and resolve a variety of data challenges.
Among all the MACH14 data, the MEMS data system was the most complex and required
the most attention. The MEMS DID specified three files associated with MEMS data: file 1
—MEMS data (including subject ID, MEMS monitor ID, drug name, number of prescribed
daily doses, bottle opening date and time, time since last opening); file 2—start and stop
dates for which MEMS data were monitored; file 3—MEMS modifications, that is, periods
for which MEMS data are “missing” or non-monitored.
MEMS data system was cleaned by addressing non-use or malfunction of the MEMS caps;
wrong MEMS ID associated with the start and stop dates; time zone errors introduced by
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MEMS devices; missing data introduced by file corruption error; tracking errors, and
erroneous large doses per day.
Overall Descriptive Information
Table 1 summarizes the general information of institution, study name, interventional/
observational study, intervention description, type and length for interventional studies,
project duration, number of subjects, and length of follow-up of each study. These 16 NIH-
funded HIV adherence studies from 14 institutions and 12 states were conducted between
1997 and 2009, and included a total of 2,860 HIV subjects. The mean length of subject
follow-up was 16.5 months, ranging from 3 to 60 months. The sample size for each study
ranged from 76 to 404.
The number of measures for key MACH14 variables by study are shown in Table 2. Of the
2,860 subjects, 2,498 (87 %) have available MEMS data, with a total of 478,242 individual
MEMS openings documented; 2,776 (97 %) subjects have VL data with a total of 16,250
individual measurements. CD4 count data are available from 15 studies. There are 12,532
CD4 measurements in 2,575 subjects. Five studies collected drug resistance data using
genotype or phenotype testing at virologic failure. Of the total 2,860 participants, 236 have
tested for drug resistance with a total of 1,531 drug resistant data points collected.
Demographic Data
Subject characteristics for the pooled data system are shown in Table 3. Mean (SD) age is
41(8) years, with a range of 18–72 years. Thirty-two percent are female. Nearly half (48 %)
are Black/African American, followed by 29 % Caucasian/White, 15 % Latino/Hispanic,
and 9 % “Other”. The majority (63 %) has high school diploma, 69 % were unemployed,
and 58 % earned less than $10,000 yearly. Regarding sexual orientation, 41 % are
heterosexual, 34 % homosexual, 14 % are bisexual, and the rest (11 %) are not sure. In total,
476 (18 %) were ARV naïve subjects, who were initiating an ARV regimen.
MEMS Data
Table 4 shows the distribution of ARVs monitored, including over 30 different ARV
medications from all ARV drug classes. The most frequently monitored medications are
Nelfinavir (NFV), Lopinavir/Ritonavir (LPV), Efavirenz (EFV), Combivir (CBV), and
Indinavir (IDV), and average person months of follow-up for these medications are 4.62,
4.47, 5.89, 3.82, and 4.15, respectively. Figure 1 shows the box plots of adherence by month
for the first 12 months. In general, median adherence tended to go down from month 1 to
month 10, and then rose at months 11 and 12. The rise in adherence at months 11–12 could
be due to improved adherence in some individuals or less data at those time points from less
adherent individuals.
Viral Load and CD4 Data
Table 5 shows distributions of the recorded VL and CD4. The first recorded VL for each
subject ranges from undetectable (<50 copies/ml) up to 6.8 log10 copies/ml, with 78 %
detectable (≥50 copies/ml), and the mean of the first VL is 3.32 log10 copies/ml with vast
variation. After averaging across all the VLs that each subject had, the mean VL is 2.87
log10 copies/ml, indicating that VL level becomes lower after the first VL. For the first
recorded CD4 count, the mean is 359. After averaging across all the CD4 that each subject
had, the mean CD4 is 396, indicating that CD4 level becomes higher after the first CD4.
Liu et al. Page 7














A total of 9,996 individual substance and alcohol abuse data points were collected for 2,820
subjects over time across the 16 studies. These data, though not necessarily in all the 16
studies, included substance use, alcohol use, substance abuse treatment such as Methadone
treatment, overnight stay, symptoms withdraw from drug/alcohol, and legal problems (e.g.,
recent charges, arrests, probation and parole). Substances assessed included cocaine,
sedatives (hypnotics), stimulants, psychedelics/hallucinogens, marijuana, and heroin. About
one quarter (498/2,018) of subjects had current or recent substance abuse treatment, such as
Methadone treatment, or residential treatment; 6.2 % (25/402) injection drug users; and 8.1
% (44/546) subjects have legal problems in the past year. Of all the available 2,610
substance/alcohol users, there are 47.7 % (1,172/ 2,459) alcohol drinker and 18.7 %
(219/1,172) binge drinker in the past month. Of all the available substance users, 24.5 %
(498/2,031) subjects use marijuana, 18.1 % (368/2,034) subjects use heroin, 13.4 %
(294/2,198) use cocaine, 8.3 % (92/1,112) subjects use sedatives, 6.4 % (118/1,857) subjects
use stimulants, 1.8 % (23/1,266) subjects use psychedelics or hallucinogens, and 1.7 % (25/
1,501) subjects use ecstasy.
Clinical and Psychosocial Data
Clinical data distributions are shown in Table 6. Psychosocial measures include self-
efficacy, anxiety, depressive symptoms, general support, medication specific support,
perceived stress, coping symptom, reasons, beliefs, health survey, motivation, and
competence and concern. To resolve the issue of different measures for the same sub-
domain of anxiety, a common anxiety measure across the studies was created by re-scaling
the different anxiety measures to a z score using the mean and standard deviation of anxiety
obtained from a population norm. To create the comparable measures, we mapped the
different measures of coping onto the Brief Coping scale on a 0–100 scale.
Intervention Programs
Interventional/observational study information is shown in Table 1. Of the 16 studies, 12
were intervention studies and 4 were observational studies. For the intervention studies, the
majority had a true control arm that was mainly standard care programs. Two of the 12
interventional studies had intervention arms only (one had two intervention programs
(supportive counseling and supportive counseling with a review of MEMS data and prizes
for MEMS-verified medication-taking)) and the other had a factorial design with two
intervention arms (“pager”, “buddy” for dose reminders to combat “forgetting” and relieve
participant burden) evaluated in a factorial design. One study had a cross-over design.
Although there were different intervention programs among the studies, all programs were
designed to promote adherence to ARV medications.
Discussion
In clinical trials, meta-regression of aggregated data is the usual approach for relating
sources of variation in treatment effects to specific study characteristics. However, study-
level analyses can lead to biased assessments, and use of aggregated summary values has
many limitations for explaining the heterogeneity [7, 19–21]. Meta-analyses with individual
participant data (IPD) gathered from the constituent studies allows researchers to perform
subgroup analyses not conducted by the original studies and to add new information to the
data sets by using different statistical methods [22].
A major challenge of this super-meta approach of pooling individual data of multiple trials
together is to balance the internal differences between studies in order to build a virtual large
trial. The MACH14 approach differs from the usual individual subject level meta analysis in
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that most of the individual level meta analyses use drug trial data, while what we are
attempting is much more complicated, and requires many more post hoc alignment and
adjustment. The pooled MACH14 data system contains original measures at individual
subject level, and has the capacity and strength to evaluate heterogeneity across studies, the
relationships between subject characteristics and adherence as well as the association
between adherence and virologic and clinical outcomes.
The pooling of individual trials in MACH14 has created a unique and powerful HIV data
system with 2,860 subjects to address questions that are difficult for the individual studies.
The data system represents the largest HIV anti-retroviral MEMS adherence data system
ever assembled, which allows for specific analyses in sub-populations such as women,
specific types of substance users, and particular regimens. The data system allows for better
adjustment for potential confounding and the examination of interactions that are not
permitted by smaller studies. A further advantage of pooling trials together is that we can
use unified statistical methods which facilitate comparisons across all sites. Moreover, if
consistent patterns across sites are identified, results could be generalized by pooling data
from different geographical regions, which increases external validity.
A number of challenges associated with performing an individual level meta analysis arise
since MACH14 studies use a wide variety of methods. Although MACH14 required that all
included studies collected MEMS adherence and virologic data, and all had longitudinal
designs with at least 3 repeated measurements, original study entry criteria were not
uniformed. For example, not all studies have drug resistance data. Different studies could
collect VLs at different intervals, some with specified intervals, and others did so in the
course of subjects' routine clinical care. Furthermore, different measures were used for some
key information such as depression and different amounts of data collected for constructs
such as substance use across the different studies.
The process of transferring, cleaning and merging data has required close cooperation
among investigators from multiple sites. Although strict selection criteria were used to
ensure that the 16 selected studies were generally compatible, each individual study used
different measures of common concepts such as depression and substance abuse. This
heterogeneity led to a number of complications. Most notable is structural missing data due
to variation in variables assessed across sites (e.g., anxiety data in only 1,388 participants),
which necessarily requires some entire studies to be excluded from analyses. The mix of
observational studies with intervention studies is another potential weakness of this pooled
data system. For some types of analyses, data from observational studies and usual care
condition arms can be combined to form a non-intervention group. For some other types of
analyses, data from interventional studies can be grouped together to study intervention
effect.
The reasons and nature of missingness in this pooled dataset are widely diverse. Data could
be missing because a study collected data irregularly, a subject missed a visit, skipped an
item on a questionnaire, or even dropped out of the study. In some cases, data are missing
due purely to design and structural reasons. For example, not all studies assessed depression.
For those that did, due to differential data collection schedules, some studies collected
depression with different intervals. These structural differences in the dataset create
problems because each study had different eligibility criteria that are related to adherence. In
addition, these structural differences further complicate statistical analyses and modeling,
especially repeated measures analyses and modeling because of varying intervals and
availability of data points. Data were also missing for nonstructural reasons, such as missed
study visits by patients, skipped items on a questionnaire, or were lost to follow up. Naïve
methods for handling missing data (e.g., complete case analysis, pairwise deletion, and mean
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substitution) can introduce substantial bias, reduce precision of estimates, reduce study
power, and thus may lead to invalid study conclusions.
For MEMS missing data, we can create two versions of the hierarchical percent adherence
measure: one calculated by MEMS data only and one calculated by MEMS and enhanced by
self-reported adherence data. The latter version incorporates self-reported adherence into the
calculation to reduce the amount of missing values [7]. As self-reported adherence likely
overestimates a subject's true adherence level, repeated measures calibration models are
fitted to calibrate self-reported adherence to the metric of MEMS [7, 23, 24].
Handling missing data is an important but very complex issue. For structurally missing data,
imputation strategies may not be appropriate (e.g., imputation is not a practical approach for
obtaining missing anxiety data if a study did not assess anxiety or did not assess it at certain
time points). For other missing data situations, imputation or the use of missing indicators in
analysis may be useful. However, the frequency and degree, as well as the mechanism of
missingness (the extent to which missingness is at random), need to be carefully evaluated
for each measure before an imputation method is selected.
To address data missingness, we first evaluate the frequency and patterns of missingness of
each measures (e.g., missing completely at random (MCAR), missing at random (MAR) or
missing not at random (MNAR) [25, 26]), and then based on the nature of missingness,
determine if and which imputation approach would be appropriate. For simple situation, we
can use hot deck imputation, a non-parametric method of matching cases with missing
values to observations with observed values for the same variable. However, for complex
situations, hot deck imputation still has a potential for bias, a need for variance correction,
and a need for having an adequate number of complete cases for matching. Thus, we need to
use advanced missing data procedures such as the EM algorithm, fully Bayesian, maximum
likelihood (ML) procedures, and the parametric multiple imputation (MI) methods, which
are appropriate under general MAR conditions. ML and MI tend to yield similar results
when implemented in comparable ways.
In order to reduce the possible impact of MNAR missingness for MACH14 longitudinal
data, other known subject characteristics variables will be used in the missing data model
with MI/ML, which can reduce estimation bias due to MNAR missingness, and partially
restore lost power due to missingness [27, 28]. We will apply MNAR methods (e.g.,
selection models, pattern mixture models, and shared parameter models) to perform
sensitivity analysis to evaluate model robustness [26].
Conclusion
The MACH14 study has pooled and integrated existing data across multiple ARV adherence
studies with compatible and similar study designs. It has enabled the building of a powerful
and virtual large ART adherence study. The pooled data system with a large sample size and
strong statistical power makes it possible to study questions that are otherwise difficult or
impossible to address in a single small study. Sophisticated analytical methods that can deal
with the inherent differences among studies are described and can be used by other studies.
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Table 3
Demographic characteristics of MACH14 sample (N = 2,860)
Characteristics Sample frequency N (%) with available dataa
Age mean (SD) 41 (8.3) 2,835 (99.1)
Gender, n (%) 2,837 (99.2)
 Male 1,929 (68.0)
 Female 908 (32.0)
Education, n (%) 2,730 (95.5)
 Less than high school 663 (24.3)
 High school diploma/GED 1,715 (62.8)
 More than high school 352 (12.9)
Race, n (%) 2,789 (97.5)
 Black or African-American 1,337 (47.9)
 Caucasian or White 800 (28.7)
 Hispanic or Latino 409 (14.7)
 Asian American/Native American/Multiracial 243 (8.7)
Employment, n (%) 2,507 (87.7)
 Unemployed 1,738 (69.3)
 Employed (part-time/full-time) 769 (30.7)
Sexual orientation, n (%) 1,710 (59.8)
 Heterosexual 700 (40.9)
 Homosexual 581 (34.0)
 Bisexual 246 (14.4)
 Not sure 183 (10.7)
Born, n (%) 1,080 (37.8)
 US 901 (83.4)
 Other 179 (16.6)
Jail, n (%) 795 (27.8)
 Yes 348 (43.8)
 No 447 (56.2)
NAÏVE, n (%) 2,675 (93.5)
 NaÏve to antiretroviral medications at baseline 476 (17.8)
 Not NaÏve 2,199 (82.2)
Men who have sex with men, n (%) 2,302 (80.5)
 Yes 1,004 (43.6)
 No 684 (29.7)
 N/A (for female) 614 (25.6)
Injection drug use, n (%) 1,907 (66.7)
 Yes 357 (18.7)
 No 1,550 (81.3)
Other exposure, n (%) 1,728 (60.4)
 Yes 689 (39.9)
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Characteristics Sample frequency N (%) with available dataa
 No 1,039 (60.1)
Income, n (%) 2,317 (81.0)
 Less than 10 k 1,392 (58.2)
 10–20 k 494 (20.7)
 20–30 k 178 (7.4)
 30–40 k 112 (4.7)
 ≥40 k 141 (5.9)
 Refused 49 (2.0)
Housingb, n (%) 1,672 (58.5)
 Rent/own 842 (50.3)
 A friend's/relative's home 275 (16.4)
 Transitional/subsidized house 93 (5.6)
 Homeless shelter 23 (1.4)
 Homeless 259 (15.5)
 Residential drug facility 84 (5.0)
 Hospitalized 1 (0.1)
 Nursing home/personal care 0 (0.0)
 Other 95 (5.7)
Marriage status, n (%) 1,815 (63.5)
 Currently in a committed relationship 498 (27.4)
 Not in a committed relationship 1,288 (71.0)
 Refused or other 29 (1.6)
a
N refers to the number of people with valid values, and percentage refers to the percentage of N relative to the total sample size (N = 2,860)
b
Housing is combined from “homeless (Yes/No)” and “housing (9 categories)”, by adding all of the homeless from the “homeless” variable to the
homeless in the “housing” variable and then adding the remainder to the “Other” category of the “housing” variable































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Liu et al. Page 22
Table 6
Clinical data distributions of MACH14 sample (N = 2,860)
Characteristics Sample frequency N (%) with
available dataa
Lowest ever absolute CD4 count (cells/mm3), mean (SD) 213 (212.9) 1,207 (42.2)
Duration of known HIV status at time of enrollment (month), mean (SD) 15.9 (31) 2,118 (74.1)
Highest viral load in record (log10 copies/ml), mean (SD) 4.05 (0.7) 2,370 (82.9)
CDC stage at time of entry into study, n (%) 2,059 (72.0)
 A 174 (8.5)
 B 114 (5.5)
 C 320 (15.5)
 Unknown 1,451 (70.5)
Currently use or ever used any kind of alternative or complementary medications, treatments, or
supplements, n (%)
2,274 (79.5)
 No 687 (30.2)
 Yes 739 (32.5)
 Unknown 848 (37.3)
Ever had an HIV-related infection or malignancy or complication, n (%) 2,274 (79.5)
 No 601 (26.4)
 Yes 804 (35.4)
 Unknown 869 (38.2)
Ever taken or currently on PCP prophylaxis, n (%) 2,232 (78.0)
 No 281 (12.6)
 Yes, at enrollment 159 (7.1)
 Yes, only for a time before enrollment 12 (0.5)
 Yes, only at a time starting after enrollment 62 (2.8)
 Yes, for a time prior to enrollment and after enrollment 57 (2.6)
 Yes during the study, but unknown if prior to study 142 (6.4)
 Known 1,519 (68.1)
Ever taken or currently on TB prophylaxis, n (%) 2,017 (70.5)
 No 156 (7.7)
 Yes, at enrollment 27 (1.3)
 Yes, only for a time before enrollment 22 (1.1)
 Yes, only at a time starting after enrollment 32 (1.6)
 Yes, for a time prior to enrollment and after enrollment 15 (0.7)
 Yes during the study, but unknown if prior to study 7 (0.3)
 Unknown 1,758 (87.2)
a
N refers to the number of people with valid values, and the percentage is the percentage of the total sample (N = 2,860)
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